LUCIUS 卢修斯 布加替尼 Brigatinib非小细胞肺癌

布加替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Brigatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Each film-coated tablet contains

LUCIUS

非小细胞肺癌

Brigatinib ........
Indication:

PHARMACEUTICALS

LuciBriga is a kinase inhibitor indicated
eatment of adult patients with
anaplastic lymphoma kinase (ALK)-
positive metastatic non-small cell lung

30 Tablets

cancer (NSCLC) as detected by an FDA-
approved tesl.
Dosaoeand Use:
90 mg orally once daily for the first 7 days

LuciBriga 90

then increase to 180 mg orally once daily

FDA批准

May betaken with or without food.
Storage: in a dry place and store al 20 C 1o
25C.

Brigatinib Tablets

Warning

Keep medicine out of reach of Children. Do
not administer LuciBriga during Pregnancy
and Lactation.
PLEASESEE PACKAGE INSERT

90mg

Manufactured and Marketed by

LUCIUS

权威认证

Thongmang village, Xaythany district,
Vientiane Capital, Laos

www.luctus.la
Warning: To be sold by retall on prescrintion
ol regstered physicians only, and as diraota

口碑质量

适应症。
布加替尼是一种激酶抑制剂适用为有间变性淋巴瘤激
酶(ALK)-阳性转移非小细胞肺癌(NSCLC)患者且对用克
唑替尼[crizotinib]已进展或是不能耐受患者的治疗。
推荐剂量:
前7天每天一次口服90mg;
如果在前7天内耐受90mg,则将剂量增加至180mg
每天口服一次。